Literature DB >> 11396356

Cognitive function after systemic therapy for breast cancer.

J J Olin1.   

Abstract

An underinvestigated area of breast cancer survivorship involves the possible impairment of cognitive function following adjuvant chemohormonal therapy. Numerous reports of disturbing and disruptive changes in short- and long-term memory, attention span, concentration, and language skills have been made by breast cancer patients who have received chemotherapy. This article reviews the four published studies that have documented cognitive dysfunction following adjuvant chemohormonal therapies commonly used in breast cancer. The studies describe a subset of approximately one-third of participants who experienced long-term cognitive impairment. Patient- and treatment-related factors that may influence cognitive function are outlined. The impact of these cognitive impairments on the individual breast cancer survivor's quality of life is discussed, as is the potential overall impact of this research on future adjuvant therapy. The need for a prospective longitudinal study documenting the neuropsychological sequelae of adjuvant chemohormonal therapy is emphasized.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11396356

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  13 in total

1.  Multiple predictors of health-related quality of life in early stage breast cancer. Data from a year follow-up study compared with the general population.

Authors:  Inger Schou; Øivind Ekeberg; Leif Sandvik; Marianne J Hjermstad; Cornelia M Ruland
Journal:  Qual Life Res       Date:  2005-10       Impact factor: 4.147

2.  Cancer chemotherapy impairs contextual but not cue-specific fear memory.

Authors:  Jill E Macleod; Joyce A DeLeo; William F Hickey; Tim A Ahles; Andrew J Saykin; David J Bucci
Journal:  Behav Brain Res       Date:  2007-04-19       Impact factor: 3.332

Review 3.  A framework for assessment in oncology rehabilitation.

Authors:  Laura S Gilchrist; Mary Lou Galantino; Meredith Wampler; Victoria G Marchese; G Stephen Morris; Kirsten K Ness
Journal:  Phys Ther       Date:  2009-01-15

Review 4.  Memory and cancer: a review of the literature.

Authors:  Graham J McDougall; JoAnn S Oliver; Forrest Scogin
Journal:  Arch Psychiatr Nurs       Date:  2014-03-22       Impact factor: 2.218

5.  Astaxanthin Ameliorates Doxorubicin-Induced Cognitive Impairment (Chemobrain) in Experimental Rat Model: Impact on Oxidative, Inflammatory, and Apoptotic Machineries.

Authors:  Sara Emad El-Agamy; Amal Kamal Abdel-Aziz; Sara Wahdan; Ahmed Esmat; Samar S Azab
Journal:  Mol Neurobiol       Date:  2017-10-16       Impact factor: 5.590

6.  Self-reported cognitive impairment in patients with cancer.

Authors:  Sadhna Kohli; Jennifer J Griggs; Joseph A Roscoe; Pascal Jean-Pierre; Christopher Bole; Karen M Mustian; Renae Hill; Kelly Smith; Howard Gross; Gary R Morrow
Journal:  J Oncol Pract       Date:  2007-03       Impact factor: 3.840

Review 7.  Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments.

Authors:  Thomas W McAllister; Tim A Ahles; Andrew J Saykin; Robert J Ferguson; Brenna C McDonald; Lionel D Lewis; Laura A Flashman; C Harker Rhodes
Journal:  Curr Psychiatry Rep       Date:  2004-10       Impact factor: 5.285

Review 8.  Low neuropsychologic performance among adult cancer survivors treated with chemotherapy.

Authors:  Robert J Ferguson; Tim A Ahles
Journal:  Curr Neurol Neurosci Rep       Date:  2003-05       Impact factor: 5.081

Review 9.  Cancer, coping, and cognition: a model for the role of stress reactivity in cancer-related cognitive decline.

Authors:  Charissa Andreotti; James C Root; Tim A Ahles; Bruce S McEwen; Bruce E Compas
Journal:  Psychooncology       Date:  2014-10-06       Impact factor: 3.894

10.  Cognitive features 10 or more years after successful breast cancer survival: comparisons across types of cancer interventions.

Authors:  Christopher M Nguyen; Torricia H Yamada; Leigh J Beglinger; Joseph E Cavanaugh; Natalie L Denburg; Susan K Schultz
Journal:  Psychooncology       Date:  2012-05-14       Impact factor: 3.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.